Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Operation Warp Speed Shortlist Not Decided Yet, Says Novavax

We’re Still In The Running, Says R&D Chief

Executive Summary

Novavax gained a US Department of Defense contract for its vaccine candidate recently, and is confident its nanoparticle approach provides a good alternative to other technologies.

You may also be interested in...



Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine

Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel